Key statistics
On Friday, Newron Pharmaceuticals SpA (NP5:FRA) closed at 20.75, -38.15% below its 52-week high of 33.55, set on Jan 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 20.75 |
|---|---|
| High | 20.75 |
| Low | 20.75 |
| Bid | -- |
| Offer | -- |
| Previous close | 20.80 |
| Average volume | 1.04k |
|---|---|
| Shares outstanding | 20.01m |
| Free float | 17.24m |
| P/E (TTM) | 14.93 |
| Market cap | 370.32m CHF |
| EPS (TTM) | 1.24 CHF |
Data delayed at least 15 minutes, as of Feb 27 2026 07:09 GMT.
More ▼
- EQS-News: Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
- EQS-News: Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
- EQS-News: Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
- EQS-News: Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
- EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
- EQS-DD: Newron Pharmaceuticals S.p.A.: Luca Benatti, sell
More ▼
